Aβ peptide has dominated center stage in AD research, but the discovery last year of a tau mutation that causes a familial non-AD dementia has reawakened broader interest in tau...
The critical role of ApoE in β-amyloid deposition was demonstrated last year by Eli Lilly scientists, who crossbred APP/PS1 transgenics with an ApoE knockout and found...
There have been several reports over the years that the AD brain exhibits deficits in energy metabolism. In 1994, Yankner's group reported that sodium azide treatment increased...
The Athena Neuroscience PDAPP transgenic mice develop heavy Aβ deposits, particularly in the outer molecular layer (OML) of the dentate gyrus, a region that receives nerve projections from the entorhinal cortex...
The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania School of Medicine organized the 2nd Annual CNDR Retreat as a one day symposium entitled "Emerging Alzheimer's Disease Therapies...
Ivan Lieberburg of Elan Corporation summarized evidence over the past 15 years supporting the role of amyloid as causal in the onset and/or progression of AD. Aβ, a 42 amino acid long peptide...
Cynthia Lemere of Harvard Medical School summarized the efforts and progress of her group to develop intranasal immunotherapy for AD in transgenic mouse models of AD-like amyloidosis by delivering the human Aβ peptides through the nasal route...
Due to the illness of Blas Frangione, New York University School of Medicine, his colleague, E. M. Sigurdsson, gave this presentation on another alternative for immunotherapy of AD. Dr. Sigurdsson reviewed recent studies of transgenic mice with AD-like brain amyloidosis...
Dr. Samuel Gandy of Thomas Jefferson Medical School began his presentation by stating that since 1990, 14 of 15 epidemiological studies reported that hormone replacement therapy (HRT) reduced the relative risk of AD in postmenopausal women by about 50 percent...
Virginia M.-Y. Lee, University of Pennsylvania School of Medicine, summarized studies conducted by investigators in CNDR in collaboration with the Kung lAβ at Penn that seek to identify new therapies for AD...
Dr. Citron began his presentation by emphasizing that the cerebral deposition of Aβ is an early and critical feature of AD, and that Aβ is released from APP by the sequential action of two proteases, β-secretase and γ-secretase...
Yue-Ming Li, Merck and Company, began his presentation by reviewing the known biology of γ-secretase, a membrane-bound protease that cleaves within the transmembrane region of APP...
Dr. Sangram Sisodia provided a summary and critique of the foregoing scientific presentations wherein he outlined the strengths and weaknesses of each of the approaches discussed at the symposium...
This meeting was born of a disenchantment with the regular conference format that usually consists of numerous data-oriented talks with limited or no opportunity for critical discussion...
A special interest subgroup meeting on "Tau protein in Neurodegenerative Diseases" was organized by Gloria Lee, University of Iowa. This was a timely and stimulating meeting that was energized in large part by the recent discovery...